Founded over 160 years ago, Germany-based B. Braun is a leading hospital supplier of medical supplies and products around the globe, combining a broad product and a strong service component. Pursuing a broad-based strategy that seeks to leverage its wide array of products, a la American Hospital Supply Corp., B. Braun officials nonetheless understand the importance of having state-of-the-art products in its many technology categories. Its US business has been less successful, raising the question why strong foreign suppliers often find it difficult to crack the US marketplace. But B. Braun is anything but a cautious, conservative, family-owned company, as its long history might suggest. From manufacturing to corporate culture, the company relentlessly pursues the latest and most up-to-date approaches.
by David Cassak
Guide books describe Melsungen, Germany as one of the best preserved of all medieval German cities, and in the middle...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes, and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
